MEDTRONIC HEART VALVES DIVISION MEDTRONIC TRANSCATHETER VALVE; AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIV
|
Back to Search Results |
|
Model Number MDT-TRANS VALVE |
Device Problem
Perivalvular Leak (1457)
|
Patient Problems
Stroke/CVA (1770); Non specific EKG/ECG Changes (1817); Hemorrhage/Bleeding (1888); Valvular Insufficiency/ Regurgitation (4449)
|
Event Date 11/12/2021 |
Event Type
Injury
|
Manufacturer Narrative
|
Citation: guddeti r.; et al.Transcatheter aortic valve replacement in mixed aortic valve disease: a systematic review and meta-analysis.Eur heart j qual care clin outcomes.2022 mar 2;8(2):169-176.Doi: 10.1093/ehjqcco/qcab080.Pmid: 34788825.Online publish-ahead-of-print 12 november 2021.Earliest date of publication used for date of event.Medtronic products referenced: corevalve, evolut r (pma# p130021, product code: npt).Earliest approved product used for product code and pma#.No unique device identifier (serial/lot) numbers were provided; without this information it could not be determined whether these observations have been previously reported.Without return of the product no definitive conclusion can be made regarding the clinical observations.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
|
Event Description
|
Medtronic received information via literature regarding transcatheter aortic valve replacement (tavr) in patients with mixed aortic stenosis/insufficiency.All data were collected from a meta-analysis review.The study population among the six articles in the review included 58,879 patients who were predominantly male with a mean age of 83 years.Multiple manufacturer¿s devices were implanted in the study population; in four of the studies, some patients were implanted with a medtronic corevalve or evolut r bioprosthetic valve.No unique device identifier numbers were provided.Among all patients, all-cause pooled mortality was 18.9%.No further details were provided on the deaths.There was no statement of causal or contributory relationship between medtronic product and the deaths.Among all patients, adverse events included: moderate-severe aortic paravalvular leaks, strokes, major bleeding, vascular complications and need for permanent pacemaker implantation.Based on the available information medtronic product may have been associated with the adverse events.No additional adverse patient effects or product performance issues were reported.
|
|
Search Alerts/Recalls
|
|
|